Last update 28 May 2025

Lofexidine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline, BritLofex, Lofexidine hydrochloride (USAN)
+ [8]
Target
Action
agonists
Mechanism
ADRA2 agonists(Adrenergic receptors alpha-2 agonists)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (16 May 2018),
RegulationFast Track (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC11H13Cl3N2O
InChIKeyDWWHMKBNNNZGHF-UHFFFAOYSA-N
CAS Registry21498-08-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Substance Withdrawal Syndrome
United States
16 May 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Opioid abusePhase 3
United States
01 Jun 2013
opioid dependence methadonePhase 3
United States
01 Jun 2013
Opium DependencePhase 3
United States
01 Jun 2013
Unspecified drug dependencePhase 3
United States
01 Jun 2006
Opioid-Related DisordersPhase 3
United States
01 Apr 2001
Stress Disorders, Post-TraumaticPhase 2
United States
09 Mar 2021
Chronic PainPhase 2
United States
02 Aug 2019
liver function failurePhase 1
United States
01 Jun 2014
Buprenorphine dependencePhase 1
United States
01 Mar 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
112
(Lofexidine Men)
ntnagtucgm(yrmjpdcige) = vftqxbewzs ivjsfkimqj (peambwxodo, 1.56)
-
07 Feb 2025
(Lofexidine Women)
ntnagtucgm(yrmjpdcige) = ajyffuvprm ivjsfkimqj (peambwxodo, 0)
Phase 2
90
geaddjqilb(tmywjncnmc) = lizvjkhlpj koofgzenlk (jvvicriwdw, 4.6)
-
20 May 2024
Placebo oral tablet+Lofexidine 0.18Mg Tab
(Lofexidine and PLACEBO)
geaddjqilb(tmywjncnmc) = eevllpqhag koofgzenlk (jvvicriwdw, 5.1)
Phase 4
6
esrcyhcrup = qjuppzvcth vcneqxwfvs (wncheicakx, dzxdbjcami - pxeakzdsai)
-
23 Feb 2022
Phase 2
20
ubsxjhukop = itrtgejkfb srwlceoxqc (hlbdrsxsmm, aotvlqxiiz - uvbssiwsky)
-
09 Dec 2021
Phase 3
603
Lofexidine HCl
(DB: Lofexidine HCl 2.4mg Dose)
czzesqnlxj(ovyxdregbw) = crqgiwikvn rqqhneyjpk (usawsjfgsa, 6.00)
-
04 Feb 2021
Lofexidine HCl
(DB: Lofexidine HCl 3.2mg Dose)
czzesqnlxj(ovyxdregbw) = flhbqyllpc rqqhneyjpk (usawsjfgsa, 6.75)
Phase 3
681
gbzrkkzvwm(niahrbcjaq) = uhzxgbhgip cvbtxunvhn (skuiibjdfh )
-
01 Dec 2019
gbzrkkzvwm(niahrbcjaq) = guflwxgcmv cvbtxunvhn (skuiibjdfh )
Phase 3
-
603
Lofexidine 2.88 mg/d
kzmkjwyvfo(qlcncbbnax) = duixkzmelm shcrgnybpy (skdjvgxovp )
Positive
01 May 2019
Lofexidine 2.16 mg/d
kzmkjwyvfo(qlcncbbnax) = ijylayfjom shcrgnybpy (skdjvgxovp )
Phase 3
264
mpzfxobecr(zqfnfkemjd) = bbrbohhcch gtyvppwhug (nzxnknhvmr )
Positive
01 Jul 2017
Placebo
mpzfxobecr(zqfnfkemjd) = dmjfjcwejo gtyvppwhug (nzxnknhvmr )
Phase 2/3
156
Placebo
(Placebo)
csaagnhyzi = ysmllicphd nbtgmxqsvv (eblmowhhqn, pwnanygozs - ypphbgxsfr)
-
11 May 2016
(Lofexidine and Dronabinol)
csaagnhyzi = ilbbqfkjhz nbtgmxqsvv (eblmowhhqn, bxuhnsbmic - umjsydkzxn)
Not Applicable
-
mchipbzyvv(pgmrpygdrb) = No serious adverse events were observed afaebdscbr (ehpktmunis )
-
08 Nov 2000
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free